
Eisai to present new lecanemab and tau-targeting data at AAIC 2026
Eisai Co., Ltd. will unveil 52 new abstracts at the Alzheimer’s Association International Conference in London this July, focusing on the real-world performance of its lecanemab treatment and the development of the tau-targeting antibody etalanetug across the Alzheimer’s disease continuum.























